TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00039091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study: NCT02039128

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil or Fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil or Fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03510728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: college drinker's check up
Description: The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
Study: NCT03908879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard intraosseous (IO) catheter confirmation procedure
Description: The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Color flow Doppler intraosseous (IO) catheter confirmation procedure
Description: The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure transduction intraosseous (IO) catheter confirmation procedure
Description: The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
Study: NCT01475097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol
Description: Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
Study: NCT02529891

Intervention type: OTHER
Intervention: Measurement of VOC in exhaled air
Description: Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer

Intervention type: OTHER
Intervention: Measurement of VOC in exhaled air
Description: Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
Study: NCT02875964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalogram
Description: Implanting electrode to measure brain activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetoencephalogram
Description: Implanting electrode to measure brain activity
Study: NCT03510728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: college drinker's check up
Description: The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: college drinker's check up
Description: The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: college drinker's check up
Description: The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies Intervention
Description: This intervention component focuses on educating and promoting PBS activities in future college drinking situations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies Intervention
Description: This intervention component focuses on educating and promoting PBS activities in future college drinking situations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
Study: NCT02966899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Study: NCT00926263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: single dose, 1-hr IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: single dose, 1-hr IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-751,871, moxifloxacin, saline
Description: Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
Study: NCT01492738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
Study: NCT02315833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetium
Description: Capsule for oral administration contains L-cysteine 100mg
Study: NCT03628625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: total dose 7.5 mg per day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Folic acid for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT01581866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone HCL Capsules, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone HCL Capsules, 20 mg
Study: NCT04181073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebuliser
Description: Jet Nebuliser
Study: NCT03018821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Yiguan Decoction
Description: Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Supplemented Zimu Dan
Description: Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
Study: NCT02315833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule matching Acetium for oral administration.
Study: NCT03018821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus
Description: Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Guifu Erxian Decoction
Description: Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Supplemented Ganji Decoction
Description: Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
Study: NCT00596284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
Description: Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
Study: NCT00975650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasobol®
Description: Intra-nasal Testosterone (2 syringes), b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasobol®
Description: Intra-nasal Testosterone (2 syringes), b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasobol®
Description: Intra-nasal Testosterone (2 syringes), b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasobol®
Description: Intra-nasal Testosterone (2 syringes), b.i.d.
Study: NCT02081911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Volume Adductor Canal Block
Description: Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Volume Adductor Canal Block
Description: Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
Study: NCT04063228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Skill Group
Description: will practice the following skills as needed: bed mobility, transfer, walking, and stairs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Skill Group
Description: The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
Study: NCT03446313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movn Mobile App
Description: The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
Study: NCT03698929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Effect of Cholesterol - Egg Phase
Description: After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Effect of Cholesterol - Non-Egg Phase
Description: After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
Study: NCT01751373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal muscle activation therapy
Description: The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
Study: NCT00975650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® (Positive Control)
Description: QD administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® (Positive Control)
Description: QD administration
Study: NCT01751373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study: NCT01442090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be administered orally at a 10 mg daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: GDC-0980 will be administered orally at a 40 mg daily dose.
Study: NCT00736450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT03466931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Meals containing Milk and Milk
Study: NCT00736450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study: NCT04288297

Intervention type: PROCEDURE
Intervention: distal minimally invasive chevron osteotomy
Description: With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
Study: NCT01442519

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bacillus Calmette-Guerin
Description: The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: electromotive mitomycin
Description: BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
Study: NCT01017549

Intervention type: RADIATION
Group type: OTHER
Intervention: Electronic brachytherapy (Axxent System)
Description: 3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
Study: NCT00872781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
Study: NCT04383535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent SARS COVID-19 plasma
Description: Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
Study: NCT00654576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole
Description: patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
Study: NCT04181073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebuliser
Description: Aerogen Device
Study: NCT04666805

Intervention type: DRUG
Intervention: Tamoxifen
Description: 20 mg/d, oral administration

Intervention type: DRUG
Intervention: Toremifene
Description: 60 mg/d, oral administration

Intervention type: DRUG
Intervention: Anastrozole
Description: 1 tablet (1 mg) per day, oral administration
Study: NCT01921283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS sensor attachment
Description: For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no- BIS sensor attachment
Study: NCT01751360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472